- |||||||||| Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India
Review, Journal: Vaccination is the most effective and best way to avoid the disease of COVID-19. (Pubmed Central) - Sep 3, 2023 Among the vaccines that stimulate the host's immune system with the help of DNA are: undergoing Phase 2/3 trials including INO-4800 (International Vaccine Institute; Inovio Pharmaceuticals), Symvivo, Canada-COVID19 (AnGes, Inc.); GX-19 (Genexine, Inc.). BNT162b2
- |||||||||| Review, Journal: Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19). (Pubmed Central) - Apr 4, 2023
Intracellular delivery of nucleic acid-based vaccines and their adverse events needs further research. Considering re-emergence of the COVID-19 variants of concern, vaccine reassessment and the development of polyvalent vaccines, or pan-coronavirus strategies, is essential for effective infection prevention.
- |||||||||| rRSV-G protein/CsA (BARS13) / Advaccine Biopharma
Enrollment closed: Safety and Efficacy of BARS13 in the Elderly (clinicaltrials.gov) - Feb 2, 2023 P2, N=125, Active, not recruiting, Considering re-emergence of the COVID-19 variants of concern, vaccine reassessment and the development of polyvalent vaccines, or pan-coronavirus strategies, is essential for effective infection prevention. Enrolling by invitation --> Active, not recruiting
- |||||||||| rRSV-G protein/CsA (BARS13) / Advaccine Biopharma
Journal: RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses. (Pubmed Central) - Dec 20, 2022 A 15 amino acid sequence (FP4) within the F2 region of pre-F served as a CD4 Th epitope to facilitate the anti-G antibody response. Collectively, such a combination of the FP4 peptide with the G protein and CsA provides a novel strategy for developing a safe and maximally effective recombinant G protein-containing RSV vaccine.
- |||||||||| INO-4800 / Inovio, The Wistar Institute, INO-9112 / Inovio
Enrollment change, Trial withdrawal, Combination therapy: Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers (clinicaltrials.gov) - Nov 17, 2022 P1, N=0, Withdrawn, Collectively, such a combination of the FP4 peptide with the G protein and CsA provides a novel strategy for developing a safe and maximally effective recombinant G protein-containing RSV vaccine. N=160 --> 0 | Not yet recruiting --> Withdrawn
- |||||||||| INO-4800 / Inovio, The Wistar Institute
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: INNOVATE: Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure (clinicaltrials.gov) - Oct 13, 2022 P2/3, N=1308, Terminated, N=160 --> 0 | Not yet recruiting --> Withdrawn N=7517 --> 1308 | Trial completion date: Feb 2023 --> Sep 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2023 --> Sep 2022; The study was terminated to prioritize Inovio's COVID-19 efforts to advance a heterologous booster strategy and optimize potential impact on global public health.
- |||||||||| rRSV-G protein/CsA (BARS13) / Advaccine Biopharma
Enrollment status, Trial completion date, Trial primary completion date: Safety and Efficacy of BARS13 in the Elderly (clinicaltrials.gov) - Sep 22, 2022 P2, N=125, Enrolling by invitation, N=7517 --> 1308 | Trial completion date: Feb 2023 --> Sep 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2023 --> Sep 2022; The study was terminated to prioritize Inovio's COVID-19 efforts to advance a heterologous booster strategy and optimize potential impact on global public health. Recruiting --> Enrolling by invitation | Trial completion date: Jun 2023 --> Mar 2024 | Trial primary completion date: Sep 2022 --> Mar 2024
- |||||||||| INO-4800 / Inovio, The Wistar Institute, INO-9112 / Inovio
Trial completion date, Trial primary completion date, Combination therapy: Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers (clinicaltrials.gov) - Aug 22, 2022 P1, N=160, Not yet recruiting, Recruiting --> Enrolling by invitation | Trial completion date: Jun 2023 --> Mar 2024 | Trial primary completion date: Sep 2022 --> Mar 2024 Trial completion date: Aug 2023 --> Mar 2024 | Trial primary completion date: Aug 2023 --> Mar 2024
- |||||||||| INO-4800 / Inovio, The Wistar Institute
INO-4800 ? (Twitter) - Aug 20, 2022
- |||||||||| INO-4800 / Inovio, The Wistar Institute
Ino-4800! (Twitter) - Mar 28, 2022
- |||||||||| INO-4800 / Inovio, The Wistar Institute
Enrollment change, Trial completion date, Trial primary completion date: INNOVATE: Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure (clinicaltrials.gov) - Oct 26, 2021 P2/3, N=7517, Active, not recruiting, Active, not recruiting --> Recruiting N=401 --> 7517 | Trial completion date: Sep 2022 --> Jan 2023 | Trial primary completion date: Sep 2022 --> Jan 2023
|